|Day Low/High||38.16 / 38.62|
|52 Wk Low/High||27.88 / 40.97|
Take a pass on stocks like Kimberly-Clark or Pfizer that are bucking Wednesday's sell-off and going higher.
Tech is still the equity market's leading sector over three months -- and over most timeframes going back years.
This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
These blue chips pay shareholders handsomely in the form of dividends and share buybacks.
This market is all about being opportunistic.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks from the floor of the New York Stock Exchange.
For Pfizer, China is third largest market and a growing area of concern.
We believe the company has double-digit total return potential at its current price.
Pfizer reorganization could pave way for the company to spin off businesses.
Pfizer announced plans Wednesday to reorganize into three units.
The stock faces a lot of headwinds on a day when markets are trying to surmount trade-war woes.
The bets are coming off one table and going to another amid the tariff news, much to the consternation of the sideliners.
Here are the business stories you must know as U.S. stock futures fall sharply.
Stocks are off of their day's highs, and Pfizer has pulled back on a Trump tweet: Pfizer & others should be ashamed that they have raised drug prices for no reason. They are merely taking advantage of the poor & others unable to defend themselves, w...
The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.
Don't count on it. The fundamentals paint two very different pictures, Cramer says.
Options spreads aren't tradable with some small biotechs, making shares the only way to play.
I think it very possible that there will be a positive reaction tonight, more likely based on what Tim Cook says.
Real Money stock picks from Tim Collins, Skip Raschke, Jim Collins and Bret Jensen.
Your burning biotech questions answered in our latest mailbag.
We'll answer two of the common questions we have received so far in March.
Let's see what barriers may need to be passed before it heads its way higher.
There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.
It's time to start putting money to work in the stock market, thanks to this week's stock market pullback, especially if you have been sitting on the sidelines, according to one expert.
You might actually be grateful that stocks took one on the jaw on Monday.